FDA Greenlights Agomab's Phase 2b Crohn's Disease Trial Design
Summary
Agomab Therapeutics has reached an agreement with the FDA on the design of its Phase 2b NOV-ERA study for ontunisertib, a treatment for fibrostenosing Crohn's disease. This follows the 6-K filing earlier today, which announced the final design of the study. The trial will enroll up to 320 adults, comparing the experimental pill against placebo, with a primary endpoint at 24 weeks. This regulatory alignment is a significant de-risking milestone for Agomab's lead asset, especially given the unmet medical need in this condition. The first patient is expected to be dosed in the second half of this year.
At the time of this announcement, AGMB was trading at $11.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $577M. The 52-week trading range was $8.75 to $17.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.